**A prospective post-marketing observational study of brivaracetam in people with focal epilepsy**

**SUPPLEMENTAL MATERIAL**

Rayan Yanes, Joel Neves Briard, Tang-Duc Jeremy Nguyen, Maya Sultanem, Dang Khoa Nguyen, Steve Gibbs, Kristin Ikeda, Jeffrey Jirsch, Colin Josephson, Lysa Boisse Lomax, Véronique Cloutier, Mark Keezer

TABLE OF CONTENT

[**Supplemental Table 1**. Descriptive outcomes among participants with 3-month and 6-month follow-up data 2](#_Toc151214912)

# **Supplemental Table 1**. Descriptive outcomes among participants with 3-month and 6-month follow-up data

|  |  |  |
| --- | --- | --- |
|  | **Participants with three-month follow-up data (N=31)** | **Participants with six-month follow-up data (N=38)** |
| **BRV efficacy outcome** | n = 30 | n = 38 |
| Participants who discontinued BRV (n, %) | 2 (7) | 10 (26) |
| Participants who increased another antiseizure medication (n, %) | 1 (3) | 2 (5) |
| Participants who discontinued BRV or increased another antiseizure medication (n, %) | 3 (10) | 12 (32) |
| **Monthly seizure frequency outcomes among participants still taking BRV at follow-up** | n = 26 | n = 23 |
| Percent change in monthly seizure frequency (median, IQR) | -25% (-59%, +37%) | -40% (-100%, +50%) |
| Participants with seizure freedom (n, %) | 7 (27) | 8 (35) |
| Participants with ≥ 50% monthly seizure frequency reduction (n, %) | 8 (31) | 11 (48) |
| **Change in patient reported outcomes from baseline among participants still taking BRV at follow-up** | n = 19 | n = 20 |
| BITe score for irritability (median, IQR) | 0 (-2, +5) | 0 (-2, +5) |
| GAD-7 score for anxiety (median, IQR) | 0 (-2, +2) | 0 (-2, +1) |
| NDDI-E score for depression (median, IQR) | 0 (-3, +1) | 0 (-3, +1) |
| QOLIE-10 score for quality of life (median, IQR) | -2 (-7, +3) | -2 (-6, +3) |